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Abstract
Background Granulomatosis with polyangiitis (GPA) is a rare granulomatous vasculitis affecting small- and medium-sized 
blood vessels. In optimally treated patients with long-standing disease, the common cause of death is atherosclerosis even 
in the absence of typical risk factors.
Objective To evaluate endothelial dysfunction in GPA patients.
Methods 44 patients (21 men and 23 women) diagnosed with GPA and 53 controls matched for age, sex, BMI and typical 
risk factors for cardiovascular diseases (22 men and 31 women) were enrolled in the study. We measured each participant’s 
serum levels of vascular cell adhesion molecule-1 (VCAM-1), interleukin 6 (IL-6), and thrombomodulin. We also studied 
flow-mediated dilatation (FMD) of the brachial artery, intima-media thickness (IMT) of the common carotid artery and 
aortic stiffness using echocardiography.
Results Patients with GPA showed a 15.9% increase in serum levels of VCAM-1 (p = 0.01), 66% of IL-6 (p < 0.001) and 
50.9% of thrombomodulin (p < 0.001) compared to controls. FMD% was 48.9% lower in patients with GPA in comparison 
to controls (p < 0.001), after adjustment for potential confounders, with no differences regarding IMT or aortic stiffness. 
FMD% was negatively associated with duration of the disease (β = − 0.18 [95% CI: − 0.32 to − 0.04]), C-reactive protein 
(β = − 0.17 [95% CI: − 0.27 to − 0.07]), IL-6 (β = − 0.29 [95% CI: − 0.39 to − 0.19]), blood creatinine level (β = − 0.2 
[95% CI: − 0.3 to − 0.1]), and IMT (β = − 0.14 (− 0.24 to − 0.04). In a multiple linear regression model, kidney function, 
IMT, pack-years of smoking, diabetes and level of VCAM-1 were independent predictors of lower FMD%.
Conclusion GPA is characterized by endothelial dysfunction. FMD is a useful tool for the detection of endothelial injury.
Keywords Endothelium · Atherosclerosis · Systemic vasculitis · Ultrasonography
Introduction
Endothelium plays a key role in vascular homeostasis. It 
acts as a barrier between tissues and circulating blood and 
as a signal transducer that regulates vasomotor activity [1]. 
Activation of endothelial cells leads to upregulation of adhe-
sion molecules, such as P-selectin, E-selectin, intercellular 
adhesion molecule-1, and vascular cell adhesion molecule-1 
(VCAM-1), resulting in attachment and migration of cir-
culating leukocytes. Differentiation of migrated monocytes 
into macrophages and the subsequent uptake of lipids by 
these cells results in foam cell generation and fatty streak 
formation. Further recruitment of inflammatory cells and 
proliferation of smooth muscle cells leads to the develop-
ment of atherosclerotic plaque [2]. Endothelial function can 
be determined with a noninvasive ultrasound measurement 
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of flow-mediated dilatation (FMD) of a brachial artery. 
This is the direct measurement of the arterial endothelium’s 
response to hyperemia (shear stress) that leads to the nitric 
oxide release and vasodilatation.
Granulomatosis with polyangiitis (GPA, formerly Wegen-
er’s granulomatosis) is the common vasculitis with a preva-
lence of 3 per 100, 000 and peak incidence at the age of 
50–60. Anti-neutrophil cytoplasmic antibodies (ANCA) 
are considered as the marker of the disease and are tar-
geted against proteinase 3 (PR3). Its most common clinical 
features are granulomatous lesions of the upper and lower 
airways accompanied by the kidney failure [3, 4]. Cardiac 
involvement is infrequent in GPA, but coronary heart dis-
ease, arrhythmias, pericarditis, and nonbacterial thrombotic 
endocarditis can be present in these patients [5–8].
The increased morbidity from ischemic heart disease in 
GPA suggests that not only small vessels but also big ones 
are affected [9].
Atherosclerosis and its complications are one of the lead-
ing cause of death even in properly treated patients with 
long-standing ANCA-associated vasculitis (AAVs) [10, 
11]. However, the mechanism by which atherosclerosis is 
promoted in these diseases is not explained by the classical 
atherosclerotic risk factors and remains under investigation.
The relationship between inflammation, vascular dys-
function and atherosclerosis is well-established. Premature 
atherosclerosis has been observed in patients with chronic 
inflammatory diseases such as systemic lupus erythematosus 
[12, 13], systemic sclerosis [14, 15] and antiphospholipid 
syndrome [16, 17]. There is currently a lack of reliable data 
on endothelial injury and development of premature athero-
sclerosis in the setting of vasculitis.
Previously, a few studies have analyzed the endothelial 
damage and progression of atherosclerosis in patients with 
systemic vasculitis [18–21]. Their results, however, were 
inconsistent and limited in significance due to the small 
number of subjects studied. For this reason, we sought 
to evaluate ultrasonographic and laboratory markers of 
endothelial injury in patients with GPA, which might be 
related to the premature and accelerated atherosclerosis and 
increased risk of cardiovascular events.
Methods
A case–control observational, retrospective study was car-
ried out with approval of the Bioethics Committee of XXXX 
University Medical College (9th May 2013, number of pro-
tocol: KBET/79/B/2013). The patients were recruited from 
the population of patients at the Department of Allergy 
and Clinical Immunology at the University Hospital in 
XXXXX in the period between 2014 and 2017 who were 
in the disease flare or symptomatic. The control group was 
enrolled from the hospital personnel and relatives. They 
were selected according to matching criteria. All partici-
pants received a detailed brief of the methodology and safety 
protocols for the study and provided written consent for their 
participation.
Study groups
The case group constituted 44 patients with GPA—21 men 
and 23 women.
The control group consist of 53 individuals, 22 men and 
31 women, matched to GPA patients by gender, age, body 
mass index (BMI) and smoking habit, as well as comor-
bidities, including hypertension, hypercholesterolemia, and 
diabetes mellitus.
Patients
Each patient had a current or previous diagnosis of GPA 
based on the criteria of the American College of Rheumatol-
ogy [22]. We analyze only patients with the disease flare or 
those, who were symptomatic and diagnosed with persistent 
disease. Disease activity was measured using the Birming-
ham Vasculitis Activity Score (BVAS) [23]. Disease flare 
was defined as the presence of new symptoms (major or 
minor item in BVAS). Persistent disease was defined as the 
presence of one or more persistent symptoms attributed to 
active disease for more than 1 month but less than 3 months. 
For symptoms which occurred in patients since the onset 
of GPA and were present for more than 3 months, we used 
Vascular Damage Index (VDI) [24]. Patients with congestive 
heart failure, coronary heart disease, uncontrolled hyperten-
sion, liver failure, and cancer were excluded from the study 
(for details see supplementary material).
Main outcome variable
In this case–control study, we analyzed whether GPA is 
associated with vascular endothelial damage. We measured 
flow-mediated dilatation of the brachial artery, intima-media 
thickness of the common carotid artery, aortic stiffness as 
well as evaluated serum levels of thrombomodulin and 
VCAM-1 in GPA patients and matched control subjects.
Procedures
Laboratory analysis
Fasting blood samples were drawn in the morning from the 
antecubital vein using minimal stasis. Lipid profile, glucose, 
liver enzymes, urine, creatinine with eGFR, complete blood 
cell and platelet count were analyzed by routine laboratory 
techniques. C-reactive protein (CRP) was measured using 
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analyzer VITROS 250 Johnson & Johnson. Blood samples 
were drawn into serum separation tubes, centrifuged at 
2000×g for 20 min at room temperature, within 2 h from 
sampling. The supernatant was frozen in aliquots and stored 
at -70 °C until analysis. Interleukin-6 (IL-6), VCAM-1, and 
soluble thrombomodulin were measured using standard-
ized ELISA method (all, R&D Systems, Minneapolis, MN, 
USA). Anti-PR3 IgG was measured in all GPA subjects 
using ELISA assay (EUROIMMUN, Lübeck, Germany).
Ultrasound examinations
Ultrasound examinations were performed in a darkened, 
quiet, room, after at least 10 min rest in a supine position, 
using high-quality ultrasonograph (Sequoia 512 with a 
10 MHz linear array ultrasonic transducer, MountainView, 
Ca, USA). Before examination, the subjects refrained from 
eating for at least 10 h. Examinations were conducted by 
two independent ultrasonography experts and considered 
parameters constituted a mean of three subsequent meas-
urements. A complete transthoracic echocardiogram (TTE) 
was performed in every participant with estimation of ejec-
tion fraction of the left ventricle (EF) and systolic pulmo-
nary artery pressure in accordance to standard methods [25]. 
Flow-mediated dilatation (FMD) of the brachial artery was 
measured in accordance to Celermayer’ method [26]. Aortic 
stiffness was expressed as a percentage of aortic systolic 
diameter (ASD) and aortic diastolic diameter (ADD): aortic 
stiffness % = [(ADD − ASD)/ASD] × 100%. The intima-
media thickness (IMT) of the carotid artery was also meas-
ured and in the further analysis we used a mean value of the 
IMT measured on the right and left common carotid artery 
(for details see supplementary material).
Statistical analysis
The results were compared between the case and control 
groups using STATISTICA 12.5 Software. Continuous 
variables, all non-normal distributed values (verified by the 
Shapiro–Wilk test), were given as median and interquartile 
range and compared by the Mann–Whitney U test. Cate-
gorical variables were presented as numbers (percentages) 
and compared by χ2 test. Potential confounders were identi-
fied as: age, BMI, sex, and comorbidities such as arterial 
hypertension, diabetes mellitus and hypercholesterolemia. 
To adjust for these, obtained results of FMD%, IMT, aortic 
stiffness%, IL-6, VCAM-1, and thrombomodulin were log-
transformed and a one way covariance analysis (ANCOVA) 
was performed, to achieve the overall p value. The univariate 
linear regression tests (with adjustment for aforementioned 
confounders) were used to analyze associations between two 
selected parameters. Independent determinants of FMD% 
were established in multiple linear regression model, built 
by a forward stepwise selection procedure, verified by F Sne-
decore’s statistics, with F > 1. The R2 was used as a measure 
of the variance. To calculate odds ratios (ORs) with 95% 
confidence intervals (CIs), unconditional multivariate logis-
tic regression was performed. The cut-off values for IL-6, 
VCAM-1, FMD%, and thrombomodulin were determined 
based on receiver operating characteristic (ROC) curves. 
Results were considered statistically significant when the p 
value was less than 0.05.
Results
Characteristics of patients and controls
Demographic, clinical and laboratory characteristics of the 
studied subjects, including basic laboratory tests, ultrasound 
parameters, and cardiovascular risk factors were given in 
Table 1. Both groups were similar in age, sex, BMI as well as 
prevalence of comorbidities (hypercholesterolemia, hyper-
tension, and diabetes mellitus), smoking habit, and family 
history of cardiovascular diseases. Parameters describing 
GPA activity, as well as current and past therapy were given 
in Table 2. The median duration of the disease was 4.5 years. 
More than half of the patients had active disease at the time 
of evaluation. All of them had detectable anti-PR3. Most of 
them were being treated with steroids currently or in the past 
with other immunosuppressive agents, such as: azathioprine, 
cyclophosphamide, methotrexate, mycophenolate mofetil 
and rituximab. Additionally, GPA patients were receiv-
ing statins, beta-blockers, angiotensin-converting enzyme 
inhibitors or angiotensin receptor antagonists, diuretics and 
calcium channel blockers. Lungs were the most commonly 
involved organs, followed by paranasal sinuses and kidneys.
Basic laboratory tests and basic transthoracic 
echocardiographic parameters
As expected, GPA patients were characterized by higher 
inflammatory markers, such as CRP, IL-6 (reference range: 
0.45–9.96 pg/ml) and white blood cells, as well as impaired 
kidney function and lower hemoglobin level (Table  1). 
Moreover, there were characterized by higher triglycerides.
In TTE GPA subjects had larger left and right ventricles 
and left atria, thicker posterior walls and interventricular 
septa, as well as lower ejection fraction and higher systolic 
pulmonary artery pressure.
Laboratory markers of endothelial injury
GPA patients had a 15.9% higher levels of VCAM-1 
(p = 0.01) and a 50.9% increased thrombomodulin con-
centrations (p < 0.001) in peripheral blood, comparing to 
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healthy individuals. However, in ANCOVA analysis we 
documented that only thrombomodulin levels remained 
higher in GPA subjects after adjustment for potential 
confounders (age, sex, BMI, hypercholesterolemia, hyper-
tension, and diabetes mellitus, p < 0.001). The VCAM-1 was 
similar in GPA and control groups in this analysis (p = 0.54). 
Table 1  A summary of demographic, laboratory and echocardiographic parameters in patients with granulomatosis with polyangiitis and con-
trols
a Categorical variables are presented as numbers (percentage), continuous variables as median and interquartile range. The results which are sta-
tistically significant are marked
Patients, n* = 44 Controls, n = 53 p value
Age (years) 59 (46–65) 48 (43–61) 0.07
Male gender, number (%) 21 (47.6) 22 (41.5) 0.67
Body mass index (kg/m2) 26.1 (24.1–29.6) 26.6 (23.9–29.1) 0.93
Basic laboratory tests
 Hemoglobin (g/dl) 12.25 (10.55–13.55) 13.7 (12.7–15) < 0.001a
 Red blood cells  (103/ul) 4.13 (3.7–4.5) 4.5 (4.2–4.9) < 0.001a
 White blood cells  (103/ul) 7.46 (5.76–10.06) 5.9 (5.03–6.96) < 0.001a
 Platelet count  (103/ul) 235.5 (171–287) 225 (200–275) 0.67
 Total cholesterol (mmol/l) 4.7 (3.9–5.4) 4.9 (4.2–5.25) 0.58
 Low-density lipoprotein (mmol/l) 2.4 (1.9–3.2) 3.1 (2.5–3.6) 0.003a
 Triglycerides (mmol/l) 1.7 (1.2–2.1) 1.1 (0.7–1.5) 0.002a
 Glucose (mmol/l) 5 (4.45–5.43) 4.95 (4.72–5.2) 0.95
 Creatinine (mmol/l) 101.9 (72.5–240) 76.1 (68.3–90) 0.01a
 Urea (mmol/l) 7.55 (5.8–12.7) 4.56 (3.93–5.3) < 0.001a
 Estimated glomerular filtration rate (ml/min/1.73 m2) 60 (26–67) 60 (60–80) 0.01a
 Alanine transaminase (U/l) 21.5 (15–32) 22.5 (14–28) 0.72
 C-reactive protein (mg/dl) 7.6 (5–19.4) 1.2 (1–2.1) < 0.001a
 Interleukin-6 (pg/ml) 5.03 (3.02–10.5) 1.7 (1.08–2.16) < 0.001a
Echocardiographic parameters
 Left ventricular diastolic diameter (cm) 4.8 (4.6–5.3) 4.7 (4.5–4.9) 0.29
 Left ventricular systolic diameter (cm) 3 (3–3.4) 3 (2.9–3.1) 0.049a
 Right ventricular diameter (cm) 2.2 (2–2.3) 2.1 (1.9–2.3) 0.01a
 Left atrial diameter (cm) 3.9 (3.7–4.1) 3.7 (3.5–3.9) 0.004a
 Left ventricle posterior wall thickness (cm) 1.05 (0.9–1.2) 0.9 (0.8–1) < 0.001a
 Interventricular septum thickness (cm) 1.1 (1–1.2) 0.9 (0.8–1) < 0.001a
 Ejection fraction (%) 65 (60–68) 68 (68–70) < 0.001a
 Pulmonary artery pressure (mmHg) 32 (30–36) 32 (26–32) 0.01a
Laboratory parameters of endothelial injury
 Vascular cell adhesion molecule-1 (ng/ml) 957 (749.1–1273.4) 804.6 (694.4–936.7) 0.01a
 Thrombomodulin (ng/ml) 8.9 (5.2–1.4) 4.3 (3.9–4.7) < 0.001a
Ultrasound parameters of endothelial injury and atherosclerosis
 Relative increase of flow-mediated dilatation of a brachial artery 5.26 (4.08–8.01) 10.3 (8.89–12,5) < 0.001a
 Aortic stiffness (%) 7.14 (4–9.09) 7.4 (6.25–10.34) 0.27
 Median value of intima-media thickness of a common carotid artery (cm) 0.07 (0.06–0.08) 0.07 (0.06–0.08) 0.20
Other cardiovascular risk factors
 Hypertension n(%) 21 (50) 16 (30.2) 0.08
 Diabetes mellitus n(%) 9 (21.43) 6 (11.3) 0.2
 Hypercholesterolemia n(%) 14 (33.33) 19 (35.8) 0.68
 Smoking currently n(%) 3 (7.14) 4 (7.55) 0.9
 In the past n(%) 13 (30.95) 15 (28.3) 0.33
 Smoking (packs/years) 0 (0–15) 0 (0–3) 0.64
 Positive family history of cardiovascular diseases n(%) 9 (21.42) 7 (13.2) 0.32
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Moreover, patients with GPA had increased risk of elevated 
VCAM-1 (OR 5.75 [95% CI: 2–16.38], reference range: 
349–991 ng/ml), and thrombomodulin (OR 6.71 [95% CI: 
3.37–13.3], reference range: 2.9–5.3 ng/ml) compared to the 
healthy individuals (cut-off points: 1213.96 and 5.9 ng/ml, 
respectively). As expected, both endothelial injury mark-
ers were related to the CRP (β = 0.18 [95% CI: 0.08–0.28], 
and β = 0.28 [95% CI: 0.27–0.29], VCAM-1 and thrombo-
modulin, respectively) and IL-6 level (β = 0.27 [95% CI: 
0.15–0.39], and β = 0.4 [95% CI: 0.27–0.53], VCAM-1 and 
thrombomodulin, respectively). Moreover, we demonstrated 
strong positive association between white blood cells and 
thrombomodulin (β = 0.2 [95% CI: 0.11–0.29]). Table 3 
demonstrates the most important associations of selected 
laboratory and echocardiographic parameters after adjust-
ment for confounders with linear regression models. We 
documented positive associations between laboratory param-
eters of endothelial damage and kidney function, anti-PR3 
level as well as interventricular septum and posterior wall 
thickness (see Table 3).
GPA patients with hypertension had 30. 6% higher levels 
of VCAM-1 (1178.3 [815.2–1600.1] vs. 893.8 [635.4–959.8] 
ng/ml, p = 0.02) and 41% higher thrombomodulin levels 
(11.3 [7.8–17.6] vs. 5.9 [4.4–9.5] ng/ml, p = 0.01) than 
the remaining GPA patients. Moreover, GPA patients with 
chronic kidney disease were characterized by higher throm-
bomodulin level (11.7 [9.4–17.6) vs. 5.4 [4.4–6.9] ng/ml, 
p < 0.001) and VCAM-1 level (1258.2 [893.2–1457.7] vs. 
747.4 [546.9–917.5] ng/ml, p < 0.001). Other comorbidities 
had no impact on laboratory markers of endothelial damage. 
Patients taking statins and antihypertensive medications had 
increased thrombomodulin blood level (10.7 [7.5–15.2] vs. 
5.6 [4.1–11.9] ng/ml, p = 0.03, and 11.1 [7.1–16.1] vs. 5.4 
[3.9–8.1] ng/ml, p = 0.01, respectively), Moreover, those 
treated with antihypertensives had higher level of VCAM-1 
(1089.7 [884.5–1293.1] vs. 803.4 [520.1–905.3] ng/ml, 
p = 0.01).
In the subgroups analysis, patients in persistent disease or 
in active disease had similar results of laboratory parameters 
of endothelial injury (thrombomodulin 12.63 [5.99–18.86] 
vs. 10.18 [5.24–11.4] ng/ml, p = 0.19, VCAM-1 1099.05 
[863.94–1263.64] vs. 1065.82 [745.64–1273.38] ng/ml, 
p = 0.58).
Ultrasound parameters of endothelial injury
GPA patients had 48.9% decrease in FMD% compared to 
controls (p < 0.001, also after adjustment for potential con-
founders: age, sex, BMI, hypercholesterolemia, hyperten-
sion, diabetes mellitus p < 0.001), and markedly higher risk 
of diminished FMD% defined as values below the cut-off 
point of 8.51 (OR 4.9 [95% CI: 2.88–8.23]).
In Table 3 are given selected associations of FMD% with 
other laboratory and ultrasound parameters. As presented, 
FMD% was negatively associated with white blood cells (β 
= − 0.24 [95% CI: − 0.32 to − 0.15]), CRP (β = − 0.17 [95% 
CI: − 0.27 to − 0.07]), IL-6 (β = − 0.29 [95% CI: − 0.39 
to − 0.19]) and the blood creatinine level (β = − 0.2 [95% 
CI:− 0.3 to − 0.1]) in univariate linear regression models. 
Interestingly, FMD% was also negatively related to smoking 
Table 2  Clinical characteristics of the patients (n = 44) with granulo-
matosis with polyangiitis
Categorical variables are presented as numbers (percentage), continu-
ous variables as median and interquartile range
n number, BVAS Birmingham Vasculitis Activity Score, VDI vascular 
damage index
Patients
Duration of the disease (years) 4.5 (1–9)
Active disease n (%) 26 (59.1)
BVAS in active disease 9 (8–10)
Persistent disease n(%) 16 (36.36)
BVAS in persistent disease 4 (3–5)
Anti-proteinase 3 antibodies (IU/ml) 20.5 (5–65)
VDI score in eligible patients 3 (0–5)
Organ involvement
 Cutaneous vasculitis n (%) 13 (30.95)
 Granulomatous lesions in ears/hearing disturbances 
n (%)
11 (26.19)
 Granulomatous lesions in larynx n (%) 6 (14.63)
 Paranasal sinuses inflammation n (%) 30 (71.42)
 Bone destruction of paranasal sinuses n(%) 16 (38.1)
 Chronic kidney disease n (%) 22 (52.38)
 Lungs n (%) 31 (73.81)
 Peripheral nerves n (%) 10 (23.8)
 Gastrointestinal system n (%) 1 (2.38)
 Heart n (%) 1 (2.38)
Treatment characteristic
 Current steroids n (%) 37 (88.1)
 Current steroids dose (mg/day of prednisone) 8 (4–20)
 Systemic steroids therapy (years) 2 (0.5–5)
Immunosuppressive treatment (currently or in the past)
 Azathioprine n (%) 12 (28.57)
 Cyclophosphamide n (%) 37 (88.1)
 Total dose of cyclophosphamide (grams) 8.15 (3.9–19)
 Methotrexate n (%) 5 (11.9)
 Mycophenolate mofetil n (%) 2 (5.26)
 Rituximab n (%) 13 (30.95)
Internal medicine medications
 Angiotensin-converting enzyme inhibitors or angio-
tensin receptor antagonists n (%)
12 (28.57)
 Statins n (%) 21 (51.22)
 Beta-blockers n (%) 17 (40.48)
 Diuretics n (%) 12 (28.57)
 Calcium channel blockers n (%) 12 (28.57)
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(packs/years) (β = − 0.33 [95% CI: − 0.44 to − 0.12)], dura-
tion of the disease (β = − 0.18 [95% CI: − 0.32 to − 0.04]), 
as well as posterior wall and interventricular septum thick-
ness (β = − 0.29 [95% CI: − 0.39 to − 0.19], β = − 0.23 
[95% CI: − 0.33 to − 0.13], respectively).
A multiple regression model showed that various factors 
independently determined FMD%, including presence of 
diabetes mellitus (β = − 0.41 [95% CI: − 0.55 to − 0.27]), 
pack-years of smoking (β = − 0.14 [95% CI: − 0.29 to 
− 0.01]), IMT (β = − 0.34 [95% CI: − 0.5 to − 0.18]), serum 
urea (β = − 0.41 [95% CI: − 0.61 to − 0.21]) or VCAM-1 (β 
= − 0.33 [95% CI: − 0.53 to − 0.13]), (Table 4).
Among GPA patients, lower FMD% was observed in 
those with hypertension (5 [2.9–5.9] vs. 6.4 [4.7–8.9], 
p = 0.01), diabetes (3.4 [2.9–5] vs. 6 [4.3–8.4], p = 0.01) and 
smoking currently or in the past (4.3 [2.9–5] vs. 6.7 [5–0.3]). 
Interestingly, only those treated with azathioprine had lower 
FMD% (4.13 [2.9–5.13] vs. 6.7 [4.9–8.4], p = 0.01) with-
out influence of other immunosuppressive drugs. Patients 
treated with statins were also characterized by decrease in 
FMD% (4.5 [2.9–5.3] vs. 6.8 [5.1–9.4], p = 0.01).
The values of aortic stiffness% and IMT were similar 
in both studied groups. Aortic stiffness% and IMT did not 
correlate with laboratory parameters of endothelial injury. 
Table 3  Correlations of selected laboratory and echocardiographic parameters in GPA patients
The resulting regression coefficients (β) were given after adjustment for age, sex, BMI, and comorbidities (hypertension, diabetes mellitus and 
hypercholesterolemia)
*The results which are statistically significant are marked
Flow-mediated dilata-
tion% β (95% CI)
Intima-media thick-
ness (cm) β (95% CI)
Aortic stiffness%, β 
(95% CI)
Vascular cell adhe-
sion molecule-1 (ng/
ml), β (95% CI)
Trombomodulin (ng/
ml), β (95% CI)
White blood cells 
 (103/ul)
− 0.24 (− 0.32 to − 
0.15)*
0.07 (− 0.02 to 0.16) − 0.23 (− 0.36 to − 
0.1)*
0.08 (− 0.02 to 0.18) 0.2 (0.11 to 0.29)*
C-reactive protein 
(mg/dl)
− 0.17 (− 0.27 to − 
0.07)*
− 0.03 (− 0.13 to 
0.07)
− 0.19 (− 0.31 to − 
0.7)*
0.18 (0.08 to 0.28)* 0.28 (0.27 to 0.29)*
Interleukin-6 (pg/ml) − 0.29 (− 0.39 to − 
0.19)*
− 0.03 (− 0.13 to 
0.07)
0.08 (− 0.06 to 0.22) 0.24 (0.14 to 0.34)* 0.29 (0.2 to 0.38)*
Creatinine(mmol/l) − 0.2 (− 0.3 to − 
0.1)*
0.18 (0.08 to 0.28)* 0.27 (0.15 to 0.39)* 0.39 (0.29 to 0.49)* 0.6 (0.53 to 0.67)*
Urea(mmol/l) − 0.06 (− 0.16 to 
0.04)
0.11 (0 to 0.22) 0.11 (− 0.04 to 0.26) 0.27 (0.06 to 0.38)* 0.63 (0.55 to 0.71)*
Estimated glomerular 
filtration rate (ml/
min/1.73 m2)
0.05 (− 0.05 to 0.15) − 0.12 (− 0.24 to 0) 0.00 (− 0.19 to 0.19) − 0.23 (− 0.36 to − 
0.1)*
− 0.48 (− 0.38 to − 
0.58)*
Interventricular sep-
tum thickness (cm)
− 0.23 (− 0.33 to − 
0.13)*
0.12 (0.01 to 0.23)* 0.01 (− 0.13 to 0.15) 0.29 (0.17 to 0.41)* 0.43 (0.33 to 0.53)*
Posterior wall thick-
ness (cm)
− 0.29 (− 0.39 to − 
0.19)*
0.16 (0.05 to 0.27)* 0.00 (− 0.14 to 0.14) 0.35 (0.24 to 0.46)* 0.5 (0.41 to 0.59)*
Flow-mediated dilata-
tion%
– − 0.12 (− 0.22 to − 
0.02)*
0.25 (0.1 to 0.4)* 0.03 (− 0.09 to 0.15) − 0.07 (− 0.17 to 0.03)
Intima-media thick-
ness (cm)
− 0.14 (− 0.24 to − 
0.04)*
– 0.00 (− 0.18 to 0.18) − 0.09 (− 0.22 to 
0.04)
0.05 (− 0.05 to 0.15)
Aortic stiffness% 0.2 (− 0.07 to 0.43) 0.00 (− 0.12 to 0.12) – 0.31 (0.17 to 0.44)* 0.16 (0.03 to 0.29)*
Vascular cell adhesion 
molecule-1 (ng/ml)
0.02 (− 0.08 to 0.12) − 0.08 (− 0.18 to 
0.02)
0.3 (0.17 to 0.43)* – 0.57 (0.49 to 0.65)*
Thrombomodulin (ng/
ml)
− 0.09 (− 0.19 to 
0.01)
0.05 (− 0.05 to 0.15) 0.19 (0.04 to 0.34)* 0.72 (0.62 to 0.82)* –
Smoking (packs/years) − 0.33 (− 0.44 to − 
0.12)*
0.04 (− 0.02 to 0.1) − 0.17 (− 0.47 to 
0.13)
− 0.2 (− 0.47 to 0.07) − 0.04 (− 0.3 to 0.2)
Steroids time of treat-
ment (years)
− 0.07 (− 0.23 to 0.1) 0.19 (0.03 to 0.35)* − 0.19 − 0.43 to 0.05 − 0.1 − 0.29 to 0.09 0.05 − 0.13 to 0.22
Duration of the 
disease
− 0.18 (− 0.32 to − 
0.04)*
0.27 (0.14 to 0.41)* 0.13 (− 0.08 to 0.34) − 0.1 (− 0.28 to 0.08) 0.09 (− 0.06 to 0.24)
Concentration of anti-
proteinase 3 antibod-
ies (IU/ml)
0.00 (− 0.14 to 0.14) − 0.08 (− 0.23 to 
0.07)
− 0.04 (− 0.24 to 
0.16)
0.19 (0. 02 to 0.36)* 0.163 (0.001 to 0.33)*
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However, IMT was related to FMD% (β = − 0.12 [95% CI: 
− 0.22 to − 0.02]), blood creatinine level (β = 0.18 [95% 
CI: 0.08 to 0.28]), duration of steroid treatment (β = 0.19 
[95% CI: 0.03 to 0.35]) duration of the disease (β = 0.27 
[95% CI: 0.14 to 0.41]), posterior wall thickness (β = 0.16 
[95% CI:0.05 to 0.27]), and interventricular septum thick-
ness (β = 0.12 [95% CI:0.01 to 0.23]) (Table 3).
In the subgroup of GPA patients with chronic kid-
ney disease IMT was higher (0.08 [0.06–0.09] vs. 0.065 
[0.055–0.075], cm p = 0.01). GPA subjects treated with 
statins and with hypertension had higher IMT than remain-
ing GPA patients (0.08 [0.07–0.09] vs. 0.06 [0.05–0.07] 
cm, p = 0.01, and 0.08 [0.07–0.09] vs. 0.06 [0.06–0.07] cm, 
p = 0.001, respectively). Only one patient had an atheroscle-
rotic plaque in the left common carotid artery.
Aortic stiffness% was negatively associated with blood 
leukocyte count (β = − 0.23 [95% CI: − 0.36 to − 0.1] and 
CRP level (β = − 0.19 [95% CI: − 0.31 to − 0.7]. Comor-
bidities and medication had no impact on aortic stiffness%.
Ultrasound parameters of endothelial injury were com-
parable between the patients in the disease flare and in 
the persistent disease (FMD% 5.92 [3.35–8.89] vs. 5.86 
[4.35–7.14], p = 0.76, IMT 0.07 [0.06–0.09] vs. 0.07 
[0.06–0.08] cm, p = 0.92, aortic stiffness% 7.93 [4.56–10.53] 
vs. 7.69 [3.85–8.82], p = 0.4).
Discussion
This study demonstrates that GPA patients suffer vascular 
endothelial damage that is manifested by increased serum 
levels of thrombomodulin and VCAM-1, as well as lower 
flow-mediated dilatation of the brachial artery. Both the 
laboratory markers of endothelial injury increase while 
FMD decreases in association with inflammatory markers, 
such as IL-6 and CRP. These observations suggest that the 
most important predictor of endothelial damage in GPA is 
a persistent systemic inflammatory state. However, multi-
ple regression analysis shows that impaired FMD was also 
independently determined by other factors, including kidney 
insufficiency, diabetes as well as smoking habit.
The associations of laboratory and ultrasound param-
eters of endothelial damage with markers of inflammation 
may indicate that the process of endothelial injury is more 
prominent in active phase of the disease. However, compar-
ing the subgroups in persistent disease or in active disease 
these parameters did not differ regardless of phase of the 
disease. According to Tervaert [27] atherosclerosis is accel-
erated in the active phase but endothelial function returns to 
normal when inflammation is pharmacologically controlled. 
Another study showed that successful immunosuppressive 
treatment improves endothelial function, reaffirming the key 
role of inflammation in pathogenesis of atherosclerosis in 
this disease [28]. Such thesis was also recognized in children 
with primary systemic vasculitis without common cardiovas-
cular risk factors [29]. Moreover, Nienhuis et al. [21] dem-
onstrated impaired endothelium-dependent vasodilatation in 
microcirculation of the hand vessels of GPA patients, even if 
they did not have clinical manifestations of atherosclerosis.
In our study, we did not document any significant differ-
ences in IMT between GPA patients and healthy controls. 
This observation stays in line with results published by De 
Souza et al. [30], who suggested that premature atheroscle-
rosis in GPA patients might be postponed by use of statins 
or prednisolone. This contradicts other reports [21, 31] that 
have shown that GPA patients are characterized by higher 
Table 4  Multiple linear regression model for a relative increase of flow-mediated dilatation of a brachial artery comparing patients and control 
group
The resulting standardized regression coefficient (β) with 95% confidence intervals (95% CI) for a factor (independent variable) indicates the 
increase/decrease in standard deviations (SDs) of dependent variable, when that particular factor increases with 1 SD and all other variables in 
the model are unchanged. The results which are statistically significant are marked *
Patients Control
β (95% CI) R2 β (95% CI) R2
Duration of the disease (years) 0.15 (− 0.08 to 0.38) 0.51 – 0.32
Total cholesterol level (mmol/l) − 0.06 (− 0.19 to 0.07) 0.07 (− 0.05 to 0.19)
Urea (mmol/l) − 0.41 (− 0.61 to − 0.21)* − 0.22 (− 0.36 to − 0.08)*
Posterior wall thickness (cm) 0.03 (− 0.15 to 0.21) − 0.41 (− 0.56 to − 0.26) *
Intima-media thickness of a common carotid 
artery (cm)
− 0.34 (− 0.50 to − 0.18)* − 0.20 (− 0.35 to − 0.05)*
Total dose of cyclophosphamide (grams) − 0.19 (− 0.41 to 0.03) –
Smoking (packs/years) − 0.14 (− 0.29 to − 0.01)* –
Diabetes mellitus − 0.41 (− 0.55 to − 0.27)* –
Vascular cell adhesion molecule-1 (ng/ml) − 0.33 (− 0.53 to − 0.13)* − 0.09 (− 0.22 to 0.04)
Adjustment statistics F = 2.84, p = 0.01 F = 4.2, p < 0.001
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IMT, indicating accelerated atherosclerosis. Potential dis-
crepancy between these results may be due to the small sam-
ple size, different treatment mode or duration of the disease 
in evaluated patients. Importantly in our study, we found that 
IMT related positively to the time course of GPA.
The reason of endothelial dysfunction in GPA remains 
unknown. However, it seems that it might be related to the 
pathogenesis of the disease and eventually its therapeutic 
possibilities. In our study, the level of anti-PR3 antibodies 
was related to markers of endothelial injury. As it has been 
shown, autoantibodies in AAVs activate neutrophils which 
then adhere to the inner vessel wall causing endothelial 
impairment by release of proteolytic enzymes and trigger-
ing vasculopathic cascade [32, 33]. Moreover, pro-inflam-
matory cytokines increased in active systemic vasculitis 
depress endothelium-dependent relaxation in vitro, as well 
as in vivo [34], while reactive oxygen species lead to oxida-
tion of lipoproteins which are responsible for endothelial 
cell injury [35].
In the study by Clarke et al. [29] the level of endothe-
lial damage biomarkers was predominantly affected by 
disease activity rather than by treatment. However, it has 
been shown that cyclophosphamide, a cytotoxic drug used 
to induce remission in AAVs patients, directly injures 
endothelial cells leading to subsequent leakage of plasma to 
the extravascular space [36]. Colleoni et al. [37] observed a 
significant drop in the level of vascular endothelial growth 
factor in breast cancer patients after oral administration of 
cyclophosphamide in small doses, which also suggests its 
anti-angiogenic effect. This finding was also confirmed by 
Folkman et al. [38], who found that systemic administration 
of cyclophosphamide, anthracyclines or paclitaxel, inhibits 
neovascularization in the mouse cornea. In cancer treatment, 
cyclophosphamide is used in higher doses than in AAVs, 
however, it should be considered as an additional factor 
of potential endothelial damage. In our study, we did not 
observe differences in parameters of endothelial injury in 
those patients treated vs. those not treated with cyclophos-
phamide or other immunosuppressive drugs, such as meth-
otrexate, mycophenolate mofetil, and rituximab (data not 
shown). Only in those treated with azathioprine the FMD% 
value was lower. There are just a few reports describing 
potential role of azathioprine in endothelial cell injury [39, 
40]. However, the majority of the GPA patients were also 
treated with steroids. Prolonged steroid therapy is associated 
with hypertension, diabetes mellitus and change in the lipid 
profile, all of which influence the risk of atherosclerosis and 
cardiovascular events [41].
It has been demonstrated that renal insufficiency might 
be related to the endothelial dysfunction in other autoim-
mune diseases [2] as well as in peritoneal dialysis [42]. 
Hypertension, one of the complications of kidney failure, 
is known to be implicated in increased arterial stiffness 
and endothelial dysfunction. Additionally, uremia has been 
considered as a nontraditional cardiovascular risk factor 
[43]. However, this relationship in GPA patients has not 
been described in previous reports [44]. In our study, we 
observed positive association of blood creatinine, as well 
as urea level with FMD%, VCAM-1, and thrombomodu-
lin. GPA patients with chronic kidney disease also had 
increased levels of VCAM-1, thrombomodulin and IMT. 
This is a novel finding of our study. Urea level in GPA 
patients was also independent predictors of lower FMD% 
in a multiple linear regression model.
The lower FMD in subjects with GPA documented in 
our study is possibly related not only to the endothelial dys-
function, but also to the arteries wall remodeling. In the 
previous study the blood vessels of these patients showed an 
increased level of matrix metalloproteinases (markers of vas-
cular remodeling) [31]. Moreover, we have found a negative 
correlation between FMD and interventricular septum and 
posterior wall thickness. We also demonstrated that patients 
with GPA are characterized by larger left and right ventricu-
lar diameters and left atrial diameter, as well as increased 
left ventricle posterior wall thickness and interventricular 
septum thickness. In our opinion, these findings are most 
likely related to the inflammatory process of the kidneys and 
lungs, the organs, most often affected by GPA. Kidney dam-
age results in overload of the circulatory system, whereas the 
inflammatory process in the lungs leads to the pulmonary 
hypertension. Both of these processes lead to the secondary 
hypertrophy of the heart cavities, which we have found in 
our patients. Observed differences might be also related to 
the cardiovascular system involvement in course of GPA and 
vessel wall remodeling, leading to the increased stiffness of 
the arteries and higher afterload, as well as heart hypertro-
phy. These findings, however, require further investigation.
Smoking currently or in the past also influenced lower 
FMD in GPA patients and it was an independent predictor 
of lower FMD.
Described changes may lead to the increased risk of car-
diovascular events, what has been previously demonstrated 
by Faurschou et al. [9]. In his study, patients with GPA had 
1.9 (95% CI: 1.4–2.4) higher risk of cardiovascular disease. 
Based on this result, we may speculate that early detec-
tion of endothelial dysfunction in GPA patients may help 
in selecting the most suitable preventive strategy. Tervaert 
[27] suggested that patients with large-vessels vasculitis 
should be treated with aspirin (75–125 mg/day) to prevent 
ischemic complications. Statins should also be advised in 
most patients with GPA for endothelial protection. Obvi-
ously, patients benefit from optimal immunosuppressive 
treatment that controls inflammation and prevents from 
consequences of GPA. However, it is necessary to keep in 
mind that immunosuppressive treatment directly leads to 
endothelial cell injury.
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Study limitation
The limited number of GPA patients decreases the power 
of our findings. However, our study group is one of the big-
gest evaluated in the literature so far in terms of endothe-
lial dysfunction. Moreover, the GPA is a rare disease and 
in our opinion every report is valuable. Patients with GPA 
had some comorbidities (diabetes mellitus, hypertension 
or kidney insufficiency), which in the majority of analyzed 
subjects were related to the systemic complications of vas-
culitis and might be considered as a consequence of GPA. 
We attempted to eliminate these confounding variables by 
an adjustment for comorbidities (hypercholesterolemia, 
hypertension, and diabetes mellitus) during statistical anal-
ysis and recruitment of controls with similar common car-
diovascular risk factors. GPA patients were younger than 
controls, but this difference did not reach statistical signifi-
cance. Finally, patients with vasculitis were being treated 
with many medications, notably immunosuppressive drugs 
and corticosteroids. The impact of the medications used on 
endothelial dysfunction was beyond the scope of our study; 
however, decreased values of FMD% in patients on statins 
and antihypertensive medications seemed to be related more 
to comorbidities (hypercholesterolemia, hypertension) than 
the drugs themselves. Nevertheless, we believe that the pre-
sented results reflect true intergroup differences.
Conclusion
In summary, the patients with GPA are characterized by 
endothelial dysfunction, which is likely related to the chronic 
systemic inflammation observed in autoimmune diseases. 
Although large observational studies are needed to verify 
whether lower FMD% is associated with increased risk of 
cardiovascular events in GPA patients, this noninvasive and 
simple ultrasound test seems to represent a new tool/predic-
tor of endothelial injury for clinical practice.
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